Your partner in radiopharmacy
Since 2004, Trasis designs, manufactures, sells and supports high performance synthesizers, dose preparation and dispensing equipment, all related consumables and shielding solutions
Products
Helping the medical community easily access new radiolabeled therapeutic and diagnostic substances.
Our nuclear medicine equipment includes automated synthesizers, dose dispensing systems, their shielding and accessories. We also develop customized synthetic methods and instruments adapted to the evolving needs of the radiochemistry industry.
Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies.
About us
In a nutshell: designer and manufacturer of radiopharma instruments, ISO 9001-certified company, medical device distributor, close to its customers and partners.
What makes us different: we consider our customers' performance as our own and we put everything in place to improve it.
Our strength: every aspect of our products: design, manufacturing, commercial service, quality and support is under our full control. Our great multidisciplinary team makes this possible.
Our final goal: enable patients to have access to a wide range of radiotracers in the safest and most timely manner.
Innovating for nuclear medicine
We develop innovating equipment which enables safe manipulation and quick access to radiolabeled therapeutic and diagnostic substances.
Drug developers
Nuclear medicine departments
Drug manufacturers
- Belgium +32 4 365 86 57 EXT 2
- France +33 9 75 18 00 72
- Canada +1 780 666 41 99
- USA +1 201 588 57 52
- South America +54 11 59 84 23 04
News & Events
TRASIS offers the widest range of PSMA tracers to be produced on the same synthesizer.
Düsseldorf, 15 October 2018.
Prostate cancer is the second leading cause of cancer death for men in many parts of the world. For imaging, PSMA-based radio tracers target the PSMA (Prostate Specific Membrane Antigen) transmembrane glycoprotein, which is strongly upregulated in prostate cancer cells. In this way, the PET tracer provides important molecular information on cancer and metastases localization within the prostate.
AllinOne family versatility proven
TRASIS EUROPE | ONE MORE SUCCESS FOR TRASIS’ FDG DUAL MARKET AUTHORIZATION
Three months after its approval by the American FDA, Trasis’ FDG Dual method obtains its Market Authorization for Belgium and the Netherlands.
Trasis and Radboud Translational Medicine (RTM) worked together and finalized the Marketing Authorization National Phase for FDG production on AllinOne synthesizers.
TRASIS EUROPE | NEW LOCAL PARTNER, MORE PROXIMITY
Ans, 11 October 2018 – We are pleased to announce that we have entered into an agreement with RQS. Ruffani Quality Solutions will be our agent and provide service support for Germany and Austria.
With decades of experience and jointly to Trasis, RQS are committed to listening to our customers in order to provide the most effective solution. Located in Heideneau, RQS is also a valued partner and able to offer technical support in Germany and Austria.